Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5Head & Neck 4Gynecologic 4Breast 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Gastrointestinal 3CNS 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Interleukin-12 × CNS × Clear all
NCT04388033 2020-06-09

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Unknown
10 enrolled
CNS

Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Neoplasms, Neuroepithelial

NCT00054405 2013-04-09

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡